Pfizer implemented a warranty programme that provided money back to insurers if the treatment did not work as expected, but it seems that was not enough to encourage uptake – despite the high ...

Pfizer has joined the ranks of companies developing cancer drugs that target both PD-1 and VEGF – one of the hottest drug classes in oncology, via a $6 billion licensing deal with China's 3SBio.